Watch APGE. Know when insiders buy.
One email the day a filing lands. Free.
APGE
Apogee Therapeutics, Inc.
No price history available
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$294.4MNET CASH —52W —SEC XBRL · TTM TO Invalid Date
Who holds it
None of the 15 tracked funds disclose APGE in their latest 13F. The funds we follow.
13F filings cover US-listed holdings and arrive up to 45 days after quarter end, so positions may have changed since.
Stakes of 5% or more
Venrock Healthcare Capital Partners III, L.P. and 6 related0.0%
“Item 4 of the Statement is hereby amended and supplemented as follows: On June 18, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with AbbVie Inc. ("AbbVie"), Andor LLC, a wholly owned subsidiary of AbbVie ("Parent"), and Andor Merger Co., a wholly owned subsi…”
Fairmount Funds Management LLC and 3 related0.0%
“Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof: Consummation of Merger On September 3, 2026, the merger (the "Merger") contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated June 18, 2026, among Andor LLC ("Parent"),…”
A 13D means the holder crossed 5% with intent beyond passive ownership and had to state a purpose; a 13G is the passive version. Every new 13D on tracked companies.